Ocuphire Pharma and Viatris Announce FDA Approval of RYZUMVI™ (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g., Tro

<p>RYZUMVI Expected to be Commercially Available in the U.S. in the First Half of 2024 FARMINGTON HILLS, Mich., and PITTSBURGH, Sept. 27, 2023 (GLOBE NEWSWIRE) — Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders and Viatris Inc. […]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/ocuphire-pharma-and-viatris-announce-fda-approval-of-ryzumvi-phentolamine-ophthalmic-solution-0-75-eye-drops-for-the-treatment-of-pharmacologically-induced-mydriasis-produced-by-adrenergic/">Ocuphire Pharma and Viatris Announce FDA Approval of RYZUMVI™ (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g., Tropicamide) Agents</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>